4/25
08:01 am
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.
Low
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.
4/25
07:46 am
xoma
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) [Yahoo! Finance]
Low
Report
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) [Yahoo! Finance]
4/25
07:30 am
xoma
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Low
Report
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
4/3
09:29 am
xoma
XOMA Corporation Announces Closing of Tender Offer [Yahoo! Finance]
Low
Report
XOMA Corporation Announces Closing of Tender Offer [Yahoo! Finance]
4/3
09:00 am
xoma
XOMA Corporation Announces Closing of Tender Offer
Medium
Report
XOMA Corporation Announces Closing of Tender Offer
3/21
07:30 am
xoma
XOMA Declares Quarterly Preferred Stock Dividends
Low
Report
XOMA Declares Quarterly Preferred Stock Dividends
3/19
04:19 pm
xoma
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. [Yahoo! Finance]
Low
Report
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. [Yahoo! Finance]
3/19
04:05 pm
xoma
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
Low
Report
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
3/8
07:52 am
xoma
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value [Yahoo! Finance]
Low
Report
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value [Yahoo! Finance]
3/8
07:30 am
xoma
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
Low
Report
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
2/28
07:48 am
xoma
XOMA to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
Neutral
Report
XOMA to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
2/28
07:30 am
xoma
XOMA to Present at Upcoming Investor Conferences in March
Low
Report
XOMA to Present at Upcoming Investor Conferences in March
2/16
02:36 pm
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.
Low
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.
2/16
08:13 am
xoma
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share [Yahoo! Finance]
Medium
Report
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share [Yahoo! Finance]
2/16
08:13 am
xoma
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right [Yahoo! Finance]
Medium
Report
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right [Yahoo! Finance]
2/16
08:00 am
xoma
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Medium
Report
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right